Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top
Cut 89% covid risks: any investing plan for recovery stocks?
Views 114K Contents 89

Jumping aboard the Pfizer Train

$Pfizer(PFE.US)$ has recently announced overwhemingly positive results from a clinical study of its Covid-19 pill Paxlovid. It appears highly probable that Paxlovid would win authorization and the pill may even start selling before the end of the year . The market reacted positively to the news with huge gains for the stock price of $Pfizer(PFE.US)$. Investors hoping to jump aboard the $Pfizer(PFE.US)$ train to profit from the antiviral pill could be a little late to join the party. Still, there are other reasons to like the stock. The valuation of $Pfizer(PFE.US)$ remains attractive and the stock is still trading at a bargain, considering its growth prospects in the near term and long term. With the huge potential for Paxlovid, the cash stockpile for $Pfizer(PFE.US)$ should continue to increase greatly. The success of its battle against Covid-19 should give the company even more flexibility to make acquisitions and other business development deals that could bring about further growth. $Pfizer(PFE.US)$ appears to be a fast growing company on the basis of its coronavirus revenue as well as having a bigger, more effective pipeline of related projects.
$Nasdaq Composite Index(.IXIC.US)$
$S&P 500 Index(.SPX.US)$
$AstraZeneca(AZN.US)$
$BioNTech(BNTX.US)$
$Johnson & Johnson(JNJ.US)$
$Merck & Co(MRK.US)$
$Moderna(MRNA.US)$
$Novavax(NVAX.US)$
$Ocugen(OCGN.US)$
Jumping aboard the Pfizer Train
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
5
9
39
+0
40
Translate
Report
138K Views
Comment
Sign in to post a comment

View more comments...

avatar
Moo Contributor
Be Hopeful when others are Fearful
7229Followers
12Following
8589Visitors
Follow